Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ornella Massa is active.

Publication


Featured researches published by Ornella Massa.


Journal of Clinical Investigation | 2008

Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus

Carlo Colombo; Ottavia Porzio; Ming Liu; Ornella Massa; Mario Vasta; Silvana Salardi; Luciano Beccaria; Carla Monciotti; Sonia Toni; Oluf Pedersen; Torben Hansen; Luca Federici; Roberta Pesavento; Francesco Cadario; Giorgio Federici; Paolo Ghirri; Peter Arvan; Dario Iafusco; Fabrizio Barbetti

Permanent neonatal diabetes mellitus (PNDM) is a rare disorder usually presenting within 6 months of birth. Although several genes have been linked to this disorder, in almost half the cases documented in Italy, the genetic cause remains unknown. Because the Akita mouse bearing a mutation in the Ins2 gene exhibits PNDM associated with pancreatic beta cell apoptosis, we sequenced the human insulin gene in PNDM subjects with unidentified mutations. We discovered 7 heterozygous mutations in 10 unrelated probands. In 8 of these patients, insulin secretion was detectable at diabetes onset, but rapidly declined over time. When these mutant proinsulins were expressed in HEK293 cells, we observed defects in insulin protein folding and secretion. In these experiments, expression of the mutant proinsulins was also associated with increased Grp78 protein expression and XBP1 mRNA splicing, 2 markers of endoplasmic reticulum stress, and with increased apoptosis. Similarly transfected INS-1E insulinoma cells had diminished viability compared with those expressing WT proinsulin. In conclusion, we find that mutations in the insulin gene that promote proinsulin misfolding may cause PNDM.


Diabetologia | 2001

High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI

Ornella Massa; Franco Meschi; Antonio L. Cuesta-Muñoz; A. Caumo; Franco Cerutti; Sonia Toni; Valentino Cherubini; L. Guazzarotti; Nicoletta Sulli; Franz M. Matschinsky; R. Lorini; Dario Iafusco; Fabrizio Barbetti

Aims/hypothesis. The aim of this study was to assess the prevalence of glucokinase gene mutations in Italian children with MODY and to investigate genotype/phenotype correlations of the mutants. Methods. Screening for sequence variants in the glucokinase gene was performed by denaturing gradient gel electrophoresis and direct sequencing in 132 children with maturity onset diabetes of the young (MODY) and in 9 children with chronic fasting hyperglycaemia but without laboratory evidence for Type I (insulin-dependent) diabetes mellitus and with normoglycaemic parents (“non-classical” MODY). Results. Altogether 54 mutations were identified in the MODY group (54/132 or 41 %) and 3 among the “non-classical” MODY individuals (3/9 or 33 %). Paternity testing indicated that the latter mutations have arisen de novo. Mean fasting plasma glucose concentrations of the children with the mutant glucokinase was in the expected impaired fasting glucose range. In contrast, results of the oral glucose tolerance test showed a wide range from normal glucose tolerance (Group 1: 2-h OGTT = 6.7 ± 1.1 mmol/l; 11 patients) to diabetes (Group 2: 2-h OGTT = 11.5 ± 0.5 mmol/l; 9 patients), with the remaining in the impaired glucose tolerance range. Disruptive mutations (i. e. nonsense, frameshifts, splice-site) were equally represented in Groups 1 and 2 and were not clearly associated with an impaired first-phase insulin response. Surprisingly, 5 out of 11 children (or 45 %) in Group 1 were found to be overweight but no children in Group 2 were overweight. Sensitivity index (SI), calculated by a recently described method, was found to be significantly lower in Group 2 than in Group 1 (SI Group 2 = 0.0013 ± 0.0009 ml Kg–1 min–1/μU/ml; SI Group 1 = 0.0068 ± 0.0048, p < 0.0035). Conclusion/interpretation. Mutations in glucokinase are the first cause of MODY among Italian children selected through a low threshold limit of fasting plasma glucose (i. e. > 5.5 mmol). The lack of correlation between the molecular severity of glucokinase mutations, insulin secretion at intravenous glucose tolerance test and differences in glucose tolerance suggests that factors outside the beta cell are also involved in determining post-load glucose concentrations in these subjects. Our results seem to indicate that the differences observed in the 2-h responses at the OGTT among children with MODY 2 could be related to individual differences in insulin sensitivity. [Diabetologia (2001) 44: 898–905]


The FASEB Journal | 2002

Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient

Francesca Bernassola; Massimo Federici; Marco Corazzari; Alessandro Terrinoni; Marta Letizia Hribal; Vincenzo De Laurenzi; Marco Ranalli; Ornella Massa; Giorgio Sesti; W.H. Irwin McLean; Gennaro Citro; Fabrizio Barbetti; Gerry Melino

Transglutaminase 2 (TGase 2) is a Ca+2‐ dependent enzyme that catalyzes both intracellular and extracellular cross‐linking reactions by transamidation of specific glutamine residues. TGase 2 is known to be involved in the membrane‐mediated events required for glucose‐stimulated insulin release from the pancreatic β cells. Here we show that targeted disruption of TGase 2 impairs glucose‐stimulated insulin secretion. TGase 2‐/‐mice show glucose intolerance after intraperitoneal glucose loading. TGase 2‐/‐mice manifest a tendency to develop hypoglycemia after administration of exogenous insulin as a consequence of enhanced insulin receptor substrate 2 (IRS‐2) phosphorylation. We suggest that the increased peripheral sensitivity to insulin partially compensates for the defective secretion in this animal model. TGase 2‐/‐mouse phenotype resembles that of the maturity‐onset diabetes of young (MODY) patients. In the course of screening for human TGase 2 gene in Italian subjects with the clinical features of MODY, we detected a missense mutation (N333S) in the active site of the enzyme. Collectively, these results identify TGase 2 as a potential candidate gene in type 2 diabetes.—Bernassola, F., Federici, M., Corazzari, M., Terrinoni, A., Hribal, M. L., De Laurenzi, V., Ranalli, M., Massa, O., Sesti, G., Mclean, W. H. I., Citro, G., Barbetti, F., Melino, G. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. FASEB J. 16, 1371–1378 (2002)


Diabetes Care | 2009

Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families

Renata Lorini; Catherine Klersy; Giuseppe d'Annunzio; Ornella Massa; Nicola Minuto; Dario Iafusco; Christine Bellanné-Chantelot; Anna Paola Frongia; Sonia Toni; Franco Meschi; Franco Cerutti; Fabrizio Barbetti

OBJECTIVE To investigate the prevalence of maturity-onset diabetes of the young (MODY) in Italian children with incidental hyperglycemia. RESEARCH DESIGN AND METHODS Among 748 subjects age 1–18 years with incidental hyperglycemia, minimal diagnostic criteria for MODY were met by 172 families. Mutational analyses of the glucokinase (GCK) and hepatocyte nuclear factor 1α (HNF1Α) genes were performed. RESULTS We identified 85 GCK gene mutations in 109 probands and 10 HNF1Α mutations in 12 probands. In GCK patients, the median neonatal weight and age at the first evaluation were lower than those found in patients with HNF1A mutations. Median fasting plasma glucose and impaired fasting glucose/impaired glucose tolerance frequency after oral glucose tolerance testing were higher in GCK patients, who also showed a lower frequency of diabetes than HNF1A patients. CONCLUSIONS GCK mutations are the prevailing cause of MODY (63.4%) when the index case is recruited in Italian children with incidental hyperglycemia.


Diabetes Care | 2009

Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies

Riccardo Bonfanti; Carlo Colombo; Valentina Nocerino; Ornella Massa; Vito Lampasona; Dario Iafusco; Matteo Viscardi; Giuseppe Chiumello; Franco Meschi; Fabrizio Barbetti

OBJECTIVE—Heterozygous, gain-of-function mutations of the insulin gene can cause permanent diabetes with onset ranging from the neonatal period through adulthood. The aim of our study was to screen for the insulin gene in patients who had been clinically classified as type 1 diabetic but who tested negative for type 1 diabetes autoantibodies. RESEARCH DESIGN AND METHODS—We reviewed the clinical records of 326 patients with the diagnosis of type 1 diabetes and identified seven probands who had diabetes in isolation and were negative for five type 1 diabetes autoantibodies. We sequenced the INS gene in these seven patients. RESULTS—In two patients whose diabetes onset had been at 2 years 10 months of age and at 6 years 8 months of age, respectively, we identified the mutation GB8S and a novel mutation in the preproinsulin signal peptide (ASignal23S). CONCLUSIONS—Insulin gene mutations are rare in absolute terms in patients classified as type 1 diabetic (0.6%) but can be identified after a thorough screening of type 1 diabetes autoantibodies.


Molecular Endocrinology | 2009

Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene

Fabrizio Barbetti; Nadia Cobo-Vuilleumier; Carlo Dionisi-Vici; Sonia Toni; Paolo Ciampalini; Ornella Massa; Pablo Rodriguez-Bada; Carlo Colombo; Lorenzo Lenzi; Maria Adelaida Garcia-Gimeno; Francisco Javier Bermúdez-Silva; Fernando Rodríguez de Fonseca; Patrizia Banin; Juan Carlos Aledo; Elena Baixeras; Pascual Sanz; Antonio L. Cuesta-Muñoz

Glucokinase is essential for glucose-stimulated insulin release from the pancreatic beta-cell, serving as glucose sensor in humans. Inactivating or activating mutations of glucokinase lead to different forms of glucokinase disease, i.e. GCK-monogenic diabetes of youth, permanent neonatal diabetes (inactivating mutations), and congenital hyperinsulinism, respectively. Here we present a novel glucokinase gene (GCK)-activating mutation (p.E442K) found in an infant with neonatal hypoglycemia (1.5 mmol/liter) and in two other family members suffering from recurrent hypoglycemic episodes in their childhood and adult life. In contrast to the severe clinical presentation in the index case, functional studies showed only a slight activation of the protein (relative activity index of 3.3). We also report on functional studies of two inactivating mutations of the GCK (p.E440G and p.S441W), contiguous to the activating one, that lead to monogenic diabetes of youth. Interestingly, adult family members carrying the GCK pE440G mutation show an unusually heterogeneous and progressive diabetic phenotype, a feature not typical of GCK-monogenic diabetes of youth. In summary, we identified a novel activating GCK mutation that although being associated with severe neonatal hypoglycemia is characterized by the mildest activation of the glucokinase enzyme of all previously reported.


Journal of Proteomics | 2013

Serological proteome analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes

Ornella Massa; Massimo Alessio; Lucia Russo; Giovanni Nardo; Bonetto; Federico Bertuzzi; A Paladini; D Iafusco; P Patera; Giorgio Federici; Tarcisio Not; C Tiberti; R Bonfanti; Fabrizio Barbetti

UNLABELLED Type 1 diabetes (T1D) is an autoimmune disease characterized by the presence of circulating autoantibodies directed against proteins of islet beta-cell. Autoantibody testing is used for diagnostic purposes; however, up to 2-5% of patients who are clinically diagnosed with T1D are found negative for known antibodies, suggesting that the T1D autoantigen panel is incomplete. With the aim of identifying new T1D autoantigen(s), we used sera from subjects clinically diagnosed with T1D, but who tested negative for the four T1D autoantibodies currently used in clinical practice and for genes responsible for sporadic cases of diabetes. Sera from these patients were challenged by Western blot against the proteome from human pancreatic beta-cells resolved by 2DE. Eleven proteins were identified by MS. A radiobinding assay (RBA) was developed to test the reactivity to Rab GDP dissociation inhibitor beta (GDIβ) of T1D sera using an independent method. Depending on the construct used (open reading frame or COOH-terminus) 22% to 32% of fifty T1D sera showed increased binding to GDIβ by RBA. In addition, 15% of patients with celiac disease had raised binding to the COOH-terminus GDIβ. These results indicate that immunoproteomics is a feasible strategy for the identification of candidate T1D autoantigens. BIOLOGICAL SIGNIFICANCE Several approaches have been previously used to look for new type 1 diabetes autoantigens. With the present work we show that carefully selected sera from rare patients with diabetes both negative for the 5 autoantibodies currently used in clinical practice and for genes responsible for sporadic cases of diabetes, may be exploited in experiments utilizing human pancreatic islets extracts as a target for SERPA to identify novel candidate T1D autoantigens.


Molecular & Cellular Proteomics | 2011

Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein

Annamaria de Laurentiis; Marco Gaspari; Camillo Palmieri; Cristina Falcone; Enrico Iaccino; Giuseppe Fiume; Ornella Massa; Mariorosario Masullo; Franca Maria Tuccillo; Laura Roveda; Ubaldo Prati; Olga Fierro; Immacolata Cozzolino; Giancarlo Troncone; Pierfrancesco Tassone; Giuseppe Scala; Ileana Quinto

The UN1 monoclonal antibody recognized the UN1 antigen as a heavily sialylated and O-glycosylated protein with the apparent molecular weight of 100–120 kDa; this antigen was peculiarly expressed in fetal tissues and several cancer tissues, including leukemic T cells, breast, and colon carcinomas. However, the lack of primary structure information has limited further investigation on the role of the UN1 antigen in neoplastic transformation. In this study, we have identified the UN1 antigen as CD43, a transmembrane sialoglycoprotein involved in cell adhesion, differentiation, and apoptosis. Indeed, mass spectrometry detected two tryptic peptides of the membrane-purified UN1 antigen that matched the amino acidic sequence of the CD43 intracellular domain. Immunological cross-reactivity, migration pattern in mono- and bi-dimensional electrophoresis, and CD43 gene-dependent expression proved the CD43 identity of the UN1 antigen. Moreover, the monosaccharide GalNAc-O-linked to the CD43 peptide core was identified as an essential component of the UN1 epitope by glycosidase digestion of specific glycan branches. UN1-type CD43 glycoforms were detected in colon, sigmoid colon, and breast carcinomas, whereas undetected in normal tissues from the same patients, confirming the cancer-association of the UN1 epitope. Our results highlight UN1 monoclonal antibody as a suitable tool for cancer immunophenotyping and analysis of CD43 glycosylation in tumorigenesis.


Journal of Proteomics | 2014

A possible role of transglutaminase 2 in the nucleus of INS-1E and of cells of human pancreatic islets

Sara Sileno; Valentina D'Oria; Riccardo Stucchi; Massimo Alessio; Stefania Petrini; Valentina Bonetto; Pierre Maechler; Federico Bertuzzi; Valeria Grasso; Katia Paolella; Fabrizio Barbetti; Ornella Massa

Transglutaminase 2 (TG2) is a multifunctional protein with Ca2 +-dependent transamidating and G protein activity. Previously we reported that the role of TG2 in insulin secretion may involve cytoplasmic actin remodeling and a regulative action on other proteins during granule movement. The aim of this study was to gain a better insight into the role of TG2 transamidating activity in mitochondria and in the nucleus of INS-1E rat insulinoma cell line (INS-1E) during insulin secretion. To this end we labeled INS-1E with an artificial donor (biotinylated peptide), in basal condition and after stimulus with glucose for 2, 5, and 8 min. Biotinylated proteins of the nuclear/mitochondrial-enriched fraction were analyzed using two-dimensional electrophoresis and mass spectrometry. Many mitochondrial proteins involved in Ca2 + homeostasis (e.g. voltage-dependent anion-selective channel protein, prohibitin and different ATP synthase subunits) and many nuclear proteins involved in gene regulation (e.g. histone H3, barrier to autointegration factor and various heterogeneous nuclear ribonucleoprotein) were identified among a number of transamidating substrates of TG2 in INS-1E. The combined results provide evidence that a temporal link exists between glucose-stimulation, first phase insulin secretion and the action of TG on histone H3 both in INS-1E and human pancreatic islets. Biological significance Research into the role of transglutaminase 2 during insulin secretion in INS-1E rat insulinoma cellular model is depicting a complex role for this enzyme. Transglutaminase 2 acts in the different INS-1E compartments in the same way: catalyzing a post-translational modification event of its substrates. In this work we identify some mitochondrial and nuclear substrates of INS-1E during first phase insulin secretion. The finding that TG2 interacts with nuclear proteins that include BAF and histone H3 immediately after (2–5 min) glucose stimulus of INS-1E suggests that TG2 may be involved not only in insulin secretion, as suggested by our previous studies in cytoplasmic INS-1E fraction, but also in the regulation of glucose-induced gene transcription.


Diabetes Care | 2014

No sign of proliferative retinopathy in 15 patients with permanent neonatal diabetes with a median diabetes duration of 24 years

Dario Iafusco; Silvana Salardi; Giovanni Chiari; Sonia Toni; Ivana Rabbone; R Pesavento; B Pasquino; A de Benedictis; Giulio Maltoni; Carlo Colombo; L Russo; Ornella Massa; M Sudano; Francesco Cadario; Massimo Porta; Fabrizio Barbetti

The knowledge about the long-term consequences of diabetes with onset in the neonatal period is scanty. We investigated the impact of long-standing diabetes (>15 years) on the retina of 10 patients with permanent neonatal diabetes mellitus (PNDM) (diabetes diagnosis within 6 months of birth) associated with mutations of GCK , KCNJ11 , INS , or ABCC8 genes and of two parents carrying an INS gene mutation diagnosed with diabetes in their childhood (1,2) (Table 1, patients 1–12). Eye complications were also evaluated in three patients with diabetes onset within 1 year of age and negative for type 1A diabetes autoantibodies (2) (Table 1, patients 13–15). View this table: Table 1 Clinical and genetic features of PNDM patients with a median diabetes duration of 24 years The mean age at diagnosis of diabetes of patients with …

Collaboration


Dive into the Ornella Massa's collaboration.

Top Co-Authors

Avatar

Fabrizio Barbetti

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Dario Iafusco

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Carlo Colombo

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Franco Meschi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Sonia Toni

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Fabrizio Barbetti

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Federico Bertuzzi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Riccardo Bonfanti

Vita-Salute San Raffaele University

View shared research outputs
Researchain Logo
Decentralizing Knowledge